GPR40 has attracted an increasing research interest since studies have shown that GPR40 is also involved in metabolic syndrome (MetS), cardiovascular diseases and nonalcoholic fatty liver disease (NAFLD) by mediating FFA uptake and FFA-activated G protein-mediated signal transduction [14, 15]. Here, FFAR1 is linked to cardiovascular disorder.